About Delphi Genetics
Delphi Genetics is a Healthcare company based in Charleroi (Belgium) founded in 2001, and was acquired by Catalent in February 2021. Provider of research services in molecular biology, protein engineering, and antibody development. Delphi Genetics has raised $1.09 million across 2 funding rounds from investors including Catalent, Belfius and BNP Paribas Fortis. The company was acqui-hired. Delphi Genetics offers products and services including Plasmid DNA Manufacturing, Cell Therapy Services, and Viral Vector Production. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Proteomics.
Company details
Founded in 2001 and based in Charleroi, Belgium, Delphi Genetics operates in the biotechnology sector. Services encompass molecular biology research, protein engineering, and antibody development, with core expertise in plasmid DNA applications. Modular offerings span gene synthesis to protein production. A proprietary Staby technology has been developed for plasmid stabilization and expression without antibiotic resistance genes.
Products & Services of Delphi Genetics
Delphi Genetics offers a comprehensive portfolio of products and services, including Plasmid DNA Manufacturing, Cell Therapy Services, and Viral Vector Production.
Development and production of plasmid DNA for gene therapy applications.
Process development and CGMP manufacturing for cell therapies.
Manufacturing of viral vectors for therapeutic applications.
Apps and channels of Delphi Genetics
its YouTube channel Catalent Pharma Solutions has 7.59K subscribers and 30 videos.
Videos from Delphi Genetics
The most watched videos on Delphi Genetics's YouTube channel, Catalent Pharma Solutions (7.59K subscribers). Click a video to play it here.
More on Catalent Pharma Solutions.
Funding Insights of Delphi Genetics
Delphi Genetics has successfully raised a total of $1.09M across 2 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $3.75 million completed in June 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.09M
- Total Rounds 2
- Last Round Debt – Conventional — $3.75M
- First Round $1.09M
(Mar 2015)
- Investors Count 5
All 2 funding rounds of Delphi Genetics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2016 | $3.75M | Debt – Conventional | – | – | |
| Mar 2015 | $1.09M | Series A | – | Sambrinvest, Invest4 |
6 investors in total: 6 institutional.
Investors in Delphi Genetics
Delphi Genetics has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Catalent, Belfius and BNP Paribas Fortis.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
VC & PE fund | sambrinvest.be | Charleroi, Belgium | ||
Theodorus is engaged in managing investment funds for research innovation. | theodorus.be | Brussels, Belgium | ||
Retail banking services are offered across multiple sectors. | 1934 | bnpparibasfortis.com | Brussels, Belgium | |
Banking and insurance services are offered to individuals and businesses. | 1996 | belfius.be | Brussels, Belgium | |
Operates a real estate investment fund with multiple strategies for institutional clients. | invest4.mx | Mexico City, Mexico | ||
CDMO offering drug and biologics development services | 2007 | catalent.com | Somerset, United States |
Investor details for Delphi Genetics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Delphi Genetics
4 dated milestones of Delphi Genetics across 20 years, from founding to its latest funding, stage changes and deals.
- Founded Delphi Genetics is founded.
- Funding First funding round of $1.1M.
- Funding Latest funding round, Debt – Conventional, of $3.7M.
- Exit Acquired by Catalent.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Delphi Genetics
Complete news archive for Delphi Genetics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Delphi Genetics
Delphi Genetics was founded in 2001 and raised its 1st funding round 14 years after it was founded.
Delphi Genetics is headquartered in Charleroi, Belgium. It is registered at Charleroi, Walloon Region, Belgium.
Delphi Genetics is a funded company, having raised a total of $1.09M across 2 funding rounds to date. The company's 1st funding round was a Series A of $1.09M, raised on Mar 2015.
Founded in 2001 and based in Charleroi, Belgium, Delphi Genetics operates in the biotechnology sector. Services encompass molecular biology research, protein engineering, and antibody development, with core expertise in plasmid DNA applications. Modular offerings span gene synthesis to protein production. A proprietary Staby technology has been developed for plasmid stabilization and expression without antibiotic resistance genes.
Delphi Genetics offers Plasmid DNA Manufacturing, Cell Therapy Services, and Viral Vector Production.
Delphi Genetics has 6 investors. Key investors include Catalent, Belfius, BNP Paribas Fortis, Sambrinvest, and Invest4.
Yes. Delphi Genetics was acquired by Catalent in February 2021.